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effectiveness(3.2). Majority of oncologists noted cost of cancer drugs (63%) and patient’s 
out-of-pocket drug costs (79%) as somewhat/quite-a-bit/a lot influencing their cancer 
treatment recommendations; 90% reported (as somewhat/quite-a-bit/a lot) that cost of 
cancer drugs is expected to play a more significant role in influencing their treatment 
recommendations, over the next five years; 78% reported (as somewhat/quite-a-bit/a 
lot) that payer reimbursement policy limited their ability to offer certain cancer therapy 
to patients; 27% noted the increased use of cost-effectiveness data among payers 
when deciding reimbursement as neither-positive-nor-negative/somewhat negative/
very negative. CONCLUSIONS: In this cohort of oncologists across the US, a signifi-
cant proportion identified cancer drug cost and patient out-of-pocket costs as factors 
influencing their treatment recommendations. The respondents concurrently ranked 
drug cost-effectiveness lower than drug efficacy, safety/tolerability and impact on 
quality-of-life while addressing “value of new cancer drugs”. Impact of these oncologist 
perceptions on day-to-day clinical practice behavior warrants scrutiny.
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OBJECTIVES: To compare cancer information (CI) seekers’: a) most recent CI-seeking 
experiences, and b) self-efficacy (SE) in seeking CI across demographics, healthcare 
access, and health status. METHODS: Cross-sectional, retrospective study was con-
ducted on a representative, non-institutionalized sample of the U.S. population using 
HINTS-4 Cycle-2 data. Study sample consisted of individuals who looked for CI from 
any source (N= 1097). Response categories for all CI-seeking experience except for 
‘concern about quality of information’ were dichotomized as ‘yes’ and ‘no’. Similarly, 
response categories for self-efficacy in seeking CI were combined to form ‘low SE’, 
‘moderate SE’, and ‘high SE’. Chi-square goodness-of-fit test was applied to all vari-
ables with significance level of 0.05. Cross tabulations, Chi-square analyses were 
conducted, and weighted percentages were computed using SAS® version 9.3. Results 
with p≤ 0.05 were considered statistically significant. RESULTS: Greater proportion 
of CI seekers had characteristics as being female, Non-Hispanic White, some college 
degree, higher annual income, married, employed, having insurance, having a regu-
lar provider, without personal cancer history, with family history of cancer, or with 
‘excellent’ or ‘very good’ current health. Effort required to seek CI differed significantly 
across age, race/ethnicity, education, annual income, marital status, occupation, and 
personal cancer history. Feeling frustrated while seeking CI differed significantly 
across age, annual income, marital status, and personal cancer history. CI seekers’ 
concern about quality of information differed significantly across annual income, 
insurance, and personal cancer history. Difficulty in understanding information dif-
fered significantly across insurance. Individuals’ self-efficacy in seeking CI did not 
differ significantly across any study variables. CONCLUSIONS: Generally, CI-seeking 
experiences are likely to vary with age, race/ethnicity, education, annual income, 
occupation, marital status, and personal cancer history. Findings of this study may 
be useful in improvising current health communication interventions and to develop 
messages that are easily accessible and comprehendible by the American public.
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OBJECTIVES: The objective of this study was to analyse the financing options for 
oncology drugs in Hong Kong and estimate their time to reimbursement compared 
to other countries. METHODS: This study analysed the time to first inclusion of 
oncology drugs in the Samaritan Fund (based on the most recent SF publication) 
and compared to the time to reimbursement in countries with a similar GDP per 
capita, including Taiwan, Australia, the UK and the USA. Time to reimbursement 
was defined as the date of NHI formulary inclusion in Taiwan, publication of PBAC 
decision in Australia, publication of NICE Final Appraisal in the UK and FDA approval 
in the USA. RESULTS: Currently, only select high-cost oncology drugs are covered 
under the safety net (Samaritan Fund (SF) or Community Care Fund) by the Hospital 
Authority in Hong Kong. Of 9 assessed drugs that are currently covered under the 
SF, the reimbursement coverage of all 9 drugs in Hong Kong lagged behind Taiwan, 
Australia, the UK and the USA, from months to years. On average, the reimburse-
ment coverage of oncology drugs under SF in Hong Kong was 51.9 weeks behind 
the USA, 42.8 weeks behind Australia, 30.4 weeks behind the UK and 20.6 weeks 
behind Taiwan. These numbers were similar to the median reimbursement interval 
between Hong Kong and the USA, Australia, the UK, and Taiwan, which were 45, 
38, 32 and 17 weeks, respectively. CONCLUSIONS: The reimbursement coverage of 
oncology drugs is still limited and significantly delayed in Hong Kong compared to 
other countries with a similar GDP per capita. It not only lags behind western devel-
oped countries, like the USA, the UK and Australia, but also behind its neighbouring 
Asian country, Taiwan. There is therefore an urgent need for innovative solutions by 
the Hospital Authority to deliver access solutions for critical treatments.
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vs. $130,800, p= 0.046; age 45-49: $75,700 vs. $104,600, p= 0.001; age 50-54: $78,100 vs. 
$91,400, p= 0.059) than women ≥ 55 years (age 55-59: $87,100 vs. $91,600, p= 0.61; age 
60-64: $78,300 vs. $83,100, p= 0.48). CONCLUSIONS: Among adult women with com-
mercial insurance, RS receipt was associated with less use of adjuvant chemotherapy 
and lower medical spending among women < 55 years old but not among women 
55-64 years old.
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OBJECTIVES: Despite scientific advances, pricing for many cancer medicines 
remains based upon the content of the delivery form (e.g. infusion vial), and size 
of patient. This can cause uncertainty of budget impact & cost effectiveness, and is 
not easily related to the value delivered. New methods which bring greater certainty 
of budget impact, cost effectiveness, and value should be evaluated. METHODS: 
25 pricing schemes were researched, and two novel pricing models developed 
applicable to a range of countries were evaluated. The first approach is DRG-based 
pricing; DRG coding is used by most healthcare systems & is intervention specific. 
The second method is licensing the medicine for a specific cancer; the purchaser 
pays a licence fee for treatment, based on outcomes. RESULTS: Current pricing 
approaches are usually discounts or rebates, charged in the same manner as current 
pricing (e.g. mg/Kg). While associated with low service burden and lower costs, this 
does not reduce uncertainty or bring a closer relationship to value. Utilising new 
approaches, such as DRG pricing or licencing for medicines enables accurate predic-
tion for budget impact, enables price to be disease specific & based on value. Both 
novel methods could be developed for metastatic melanoma, NSCLC & breast cancer. 
Both methods are outcomes based (e.g. per month of progression free survival or 
overall mean or median survival), and enable purchasers to utilise medicines at a 
fixed price irrespective of weight/size of the patient, or vial size, priced according to 
value for the specific disease. Both methods would require a change in the coding 
and purchasing method for medicines by healthcare providers. CONCLUSIONS: 
New mechanisms including DRG or licensing could bring greater certainty of budget 
impact & value for specific illnesses. These methods should be piloted by healthcare 
systems to ensure practical application brings benefits, without high service burden.
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OBJECTIVES: Manufacturers are developing an increasing number of high cost ther-
apies, especially those in oncology, infectious disease, and rare/ ultra-rare diseases. 
In recent years there has also been an increase in the role of ‘nontraditional’ payers 
such as healthcare reinsurers, both in the US and globally, in biopharmaceutical 
funding and reimbursement. We assessed the global role of health care reinsurance 
as an alternate funding model for high cost treatments, including opportunities 
for manufacturers to partner with reinsurance to expand the market for innova-
tive therapies. METHODS: We conducted a literature search, scanned secondary 
resources and conducted informal interviews with healthcare reinsurance execu-
tives and other internal experts to identify key trends in reinsurance, including case 
studies and funding mechanisms. RESULTS: In the US, reinsurance is prevalent 
in the form of stop-loss insurance, which is typically purchased by employer self-
funded health plans and small group first-dollar coverage insurers, which represent 
approximately 60% of the privately insured population. Stop-loss carriers (SLCs) play 
a role in reimbursing therapies when costs exceed pre-determined ‘thresholds’ or 
‘attachment points’. In these cases, SLCs determine whether coverage criteria are 
met by examining FDA labeling, first-dollar insurer plan policies, and site of care 
(in-network vs. out-of-network providers). In Asia, reinsurance has emerged as a 
vehicle to expand the insured market for biopharmaceutical products. In China for 
example, multinational manufacturers have partnered with reinsurance carriers 
to reinsure private health insurance carriers, in effect, expanding coverage for high 
cost therapies. CONCLUSIONS: In the US and globally, manufacturers of high-cost 
treatments must proactively recognize and plan for potential roles of reinsurance 
in reimbursement of their products, especially in certain scenarios where reinsur-
ance could present a significant barrier to uptake or increases risk of non-payment, 
and where reinsurance may be leveraged to expand access to high cost treatments.
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OBJECTIVES: To assess the perception of value of cancer drugs among oncologists 
in the U.S. METHODS: A cross-sectional survey of oncologists was conducted online 
in August-September 2014 using a large panel of physicians in the US; specifically, 
medical oncologists and hematologist/oncologists currently managing > = 20 patients 
in their practice and had > = 2 years of practice experience were randomly selected 
for survey participation to be geographically representative. The survey assessed 
oncologist perception of “value of new cancer drugs”, the factors influencing their 
recommendation of cancer treatments to patients in clinical practice and other ele-
ments such as payment reforms and practice characteristics. Descriptive statistics 
are reported. RESULTS: 231 oncologists participated in the survey (medical oncolo-
gists:32%, haemato-oncologists-68%). Geographic distribution: Northeast-29%/
Midwest-23%/South-32%/West-16%; 53% and 47% were from hospital and private-
practice settings respectively. Oncologist ranking of product attributes concerning 
“value of new cancer drugs” (scale:1(most important)-4(least important)) was (mean 
scores): clinical efficacy(1.4), Safety/tolerability(2.7), impact on quality of life(2.7), cost-
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OBJECTIVES: Adjuvant cancer therapy is additional treatment administered after the 
primary treatment (usually surgery) to lower the risk of recurrence. The mechanism 
of action of the recently developed immune checkpoint inhibitors suggests they 
have potential as adjuvant therapies: by their action in enhancing the anti-tumor 
immune response, residual tumor cells may be eliminated. In this study, we identi-
fied potential challenges to pricing and reimbursement (P&R) assessment of these 
drugs as adjuvant given the likely high cost of these innovative agents. METHODS: 
We searched clinicaltrials.gov to identify current trials of immune checkpoint inhibi-
tors as adjuvant therapies. We then searched the website of the UK health technol-
ogy assessment agency, NICE, for appraisals of adjuvant cancer therapies, identified 
the corresponding evaluations by PBAC (Australia) and the SMC (Scotland) on these 
agencies’ websites, and identified key challenges. RESULTS: We identified nine trials 
with an immune checkpoint inhibitor used as adjuvant therapy, only one of which 
was Phase 3. Six NICE appraisals of pharmacological agents used as adjuvants were 
identified, all of which had also been assessed by PBAC and the SMC. Particular 
areas of concern in evaluations were the extrapolation of disease-free survival to 
overall survival, and the balance between safety and benefit in disease prevention. 
Restrictions were imposed in several decisions on the duration of adjuvant treat-
ment and the risk status of patients, dependent on the available clinical evidence. 
So far, adjuvant therapies have rarely tested acceptable cost-effectiveness thresh-
olds. CONCLUSIONS: Development of immune checkpoint inhibitors as adjuvant 
therapies is still at an early stage, but consideration of the economic and clinical 
case for these drugs will be needed to ensure successful P&R. Experience with the 
evaluation of high-cost therapies in this context is limited, so engagement will be 
needed between manufacturers and agencies to define the required evidence and 
willingness to pay.
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OBJECTIVES: Since 2011, the United Kingdom has set aside £200 million per year 
through the Cancer Drug Fund (CDF) to pay for oncology treatments not reviewed or 
approved by NICE. The CDF scores drugs on progression-free survival (PFS), overall 
survival (OS), quality of life (QoL), safety, unmet need, and strength of evidence 
(SE). The scores determine if the drug will be included on the CDF priority list. 
This analysis attempts to determine the weight each score has on the reimburse-
ment decision. METHODS: All available CDF decision summaries post April 2013 
were analyzed. Scores for PFS, OS, QoL, safety, unmet need and SE were extracted 
from each decision summary. The CDF decision was classified as positive (recom-
mended) or negative (do not recommend). Deferred decisions or drugs not scored 
were excluded. A probit model was used to estimate the probability of a positive 
decision based on the scores. RESULTS: Drugs filling an unmet need, or drugs with 
the similar/improved toxicity predicted a positive reimbursement decision per-
fectly. Drugs with significantly worse toxicity predicted a negative decision perfectly. 
Because of perfect prediction, these variables (including SE) were excluded from 
the model. Of the remaining variables in the model (PFS, OS, and QoL), only OS was 
significant. An increase in OS was related to a higher probability of getting a positive 
reimbursement decision (p= .017). If OS was less than two months, the probability of 
a positive decision was 41%, but the probability of a positive decision increases to 
99% for 6-7 months OS. CONCLUSIONS: Unmet need and similar/improved toxic-
ity are perfect predictors of a positive CDF decision. If a drug do not fill an unmet 
need or has worse toxicity, improvements in OS increase the probability of a posi-
tive decision. If the drug improves OS by 6-7 months there is a 99% probability of 
a positive decision.
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OBJECTIVES: In this study, we look at the market access delays caused by lengthy 
pricing and reimbursement negotiations in the EU5. In addition, we look at the 
results of those pricing negotiations compared to the US, and the outcome with 
regards to access for specific subpopulations. METHODS: We examined over 20 
oncology NMEs with EMA approval over the last three years and looked at the 
date of initial price publication in each market, HTA agency outcomes (where 
available), and price level at launch to compare the length of the price negotiation 
and price levels across EU markets as well as with the United States. RESULTS: 
Coming to a negotiated agreement for reimbursement in France, Italy, and Spain 
typically takes over a year, but there is no recognizable trend by market. In addi-
tion, oncology pricing in the EU5 has been found to be significantly lower than the 
US by an average of 30-40%. Lastly, we found that HTA agencies such as in France 
or Germany increasingly look at sub-group analysis and find a lack of benefit in 
some patient sub-populations. CONCLUSIONS: The secret to good pulled pork is 
low temperatures and long cooking time. With low prices and long negotiations, 
EU payers have found a recipe that is working well for them, but likely giving 
oncology manufacturers indigestion. An explosion in oncology launches over the 
past years have left payers scrutinizing the added value of new products and we 
are seeing payers demonstrating little interest in making those drugs available 
to patients quickly or at an attractive price. A realignment towards a more high 
risk but high reward approach of looking for true innovation will hopefully lead 
to better patient outcomes and higher profits for pharmaceutical and biotech 
manufacturers.
OBJECTIVES: The study aims to quantify the expected impacts of different cancers 
through multiplying the incidence rate by loss-of-QALE (quality-adjusted life expec-
tancy), with QALY (quality-adjusted life year) as the common unit, to aid prevention 
policy decisions. METHODS: 464,722 patients with pathologically verified cancer 
registered in the Taiwan Cancer Registry during 1998-2009 were used to estimate 
lifetime survival through Kaplan-Meier estimation combined with a semi-para-
metric method. A convenience sample for measuring the utility value with EQ-5D 
was conducted with 11,453 cancer patients, with the results then multiplied by the 
survival functions to estimate QALE. The loss-of-QALE was calculated by subtracting 
the QALE of each cancer cohort from the life expectancy of the corresponding age- 
and gender-matched reference population. The cumulative incidence rates from age 
20 to 79 (CIR20-79) were calculated to estimate the lifetime risk of cancer for each 
organ-system. RESULTS: Liver and lung cancer were found the highest expected 
lifetime health impacts in males and females, or expected lifetime losses of 0.97 and 
0.41 QALYs that could be averted, respectively. While the priority changes for preven-
tion based on expected health impacts were slightly different for females based on 
standardized mortality rates, those of males involve a broader spectrum, including 
oral, colorectal, esophageal and stomach cancer. CONCLUSIONS: The integration 
of incidence rate with loss-of-QALE could be used to represent the expected losses 
that could be averted by prevention, which may be useful in prioritizing strategies 
for cancer control.
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OBJECTIVES: Pharmacogenomic biomarkers aid in predicting drug response and 
adverse drug reactions. Drug label provides information about these biomarkers; 
however the quality of evidence regarding biomarker use is unclear. Thus, we 
investigated the FDA-approved drug labels for the availability and quality of evi-
dence supporting the biomarkers use in conjunction with targeted therapies in dif-
ferent cancers. METHODS: We searched the US FDA website to identify the labels 
providing information on the pharmacogenomic biomarkers of the targeted can-
cer therapies. The Evaluation of Genomic Application in Practice and Prevention 
Working Group’s guideline was used to assess the clinical validity and utility of the 
referenced studies. The available evidence was graded as convincing, adequate, or 
incomplete. We also assessed the completeness of studies and recommendation 
in the label. RESULTS: Fifty-three drug-biomarker combinations were identified, 
encompassing 42 unique drugs and 23 unique biomarkers. Combinations were 
most frequently identified in breast cancer (26%), chronic myeloid leukemia (15%), 
and colorectal cancer (11%). Half of the supporting evidence in drug labels (51%) 
were not graded with convincing validity (i.e., the ability to predict the pheno-
type of interest) and more than half (60%) were incomplete pertaining to utility 
(i.e., the ability to improve measurable clinical outcomes). Complete information 
of the referenced clinical studies was included in only 11% labels, whereas 62% 
labels provided partial information. The treatment recommendations about clini-
cal decision were based on the drug’s mechanism of action in 75% of the labels 
and on drug-biomarker association in 21% of drug labels. Also, the biomarker’s 
prediction of improved drug response and contraindications was provided in 77% 
and 23% labels, respectively. CONCLUSIONS: Majority of the labels lacked con-
vincing validity and utility regarding biomarker use. As biomarkers may enhance 
clinical care, it has become extremely important for inclusion and rational 
use of pharmacogenomic information in drug labels, for optimized decision- 
making.
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OBJECTIVES: The overall incidence of breast cancer is lower in African American 
(AA) women in comparison to European American (EA) women; however AA women 
are more likely to die of the disease. National data has reported that compared to 
EA women, AA women have a poorer diet quality and are also among the highest 
consumers of added sugar. This analysis aims to explore the association of carbo-
hydrate intake and breast cancer risk among AA and EA women. METHODS: We 
evaluated the association in a case-control study including cases (breast cancer 
positive) and controls (cancer negative). Food consumption was collected using 
a Food Frequency Questionnaire. Multivariable logistic regression controlling for 
relevant breast cancer risk factors was used to calculate Odd Ratios (OR) and 95% 
Confidence Intervals (CI). RESULTS: Our sample size was 3148. Overall, EA women 
who consumed larger amounts of total carbohydrates (highest quartile) had a sig-
nificantly decreased risk of breast cancer compared to those who consumed lower 
amounts of total carbohydrates (lowest quartile) OR= 0.60; 95% CI: 0.43-0.83. In strati-
fied analyses, a stronger inverse relationship was noted amongst premenopausal 
EA women for total carbohydrates (OR= 0.48; 95% CI: 0.30-0.78) and added sugars 
(OR= 0.56; 95% CI: 0.35-0.89). Additionally in EA women with ER+ tumors, there 
was a significantly decreased risk of breast cancer for those who consumed larger 
amounts of total carbohydrates. For AA women, we found no evidence of an associa-
tion for total carbohydrates, glycemic load or added sugars. CONCLUSIONS: This 
study suggested an inverse association between carbohydrate consumption and 
breast cancer risk in EA women, particularly for those premenopausal and with 
ER+ tumors. However, we could not establish and association between carbohydrate 
consumption and breast cancer risk in AA women. Moreover, the specific types of 
carbohydrates and food sources need be studied for both EA and AA women to bet-
ter understand the association.
